Matthew Peculis
Psychiatric/Mental Health · Walpole, MANPI 1184131898
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,970 of the $41,063 with a category attached, or 65.7%. 18 manufacturers reported payments, led by Axsome Therapeutics, Inc. at 33.3% of the total. 2025 is the largest year on record at $26,956, 4.3 times the $6,250 reported in 2021. Among psychiatric/mental health clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 434 payments — averaging $94.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$14K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$13K
- AbbVie$12K
- Otsuka America Pharmaceutical, Inc.$708
- Vanda Pharmaceuticals Inc.$457
- Lundbeck LLC$417
- plus $2K from 12 others
What the payments were for
- Consulting fees$3,1888%
- Speaking & faculty fees$26,97066%
- Travel & lodging$2,7157%
- Food & beverage$7,97419%
- Education$2171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 67 | $13,666 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 116 | $12,567 |
| AbbVie | 100 | $11,594 |
| Otsuka America Pharmaceutical, Inc. | 32 | $708 |
| Vanda Pharmaceuticals Inc. | 32 | $457 |
| Lundbeck LLC | 17 | $417 |
| Teva Pharmaceuticals USA, Inc. | 13 | $374 |
| Neurocrine Biosciences, Inc. | 11 | $284 |
| Alkermes, Inc. | 9 | $204 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $157 |
| Corium, LLC | 9 | $142 |
| E.r. Squibb & Sons, L.L.C. | 6 | $140 |
| Tris Pharma Inc | 5 | $100 |
| Supernus Pharmaceuticals, Inc. | 4 | $94 |
| Sunovion Pharmaceuticals Inc. | 3 | $73 |
| Johnson & Johnson | 2 | $49 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,063 in reported general payments places this provider in the 95th percentile of 1,284 psychiatric/mental health providers in Massachusetts.
See all psychiatric/mental health providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 41 | $86,545 |
| RexultiBrexpiprazole | 31 | $73,281 |
| CaplytaLumateperone Tosylate | 36 | $66,127 |
| TrintellixVortioxetine Hydrobromide | 42 | $31,713 |
| AuvelityDextromethorphan Hbr/Bupropion | 21 | $23,168 |
| Olanzapine | 49 | $4,793 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 12 | $3,488 |
| Vilazodone Hcl | 18 | $3,266 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 59 | $2,749 |
| Bupropion XlBupropion Hcl | 45 | $2,118 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 114 | $1,649 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 77 | $1,387 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 35 | $1,375 |
| Aripiprazole | 54 | $1,315 |
| Clonazepam | 139 | $1,193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $11,594 | $86,54541 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $708 | $73,28131 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $12,567 | $66,12736 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $157 | $31,71342 claims |
| Axsome Therapeutics, Inc.Auvelity | $13,666 | $23,16821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 psychiatric/mental health providers in Massachusetts.
Other psychiatric/mental health in Walpole
- Brianne LienkampMarion$121K
- Ashley BakerQuincy$54K
- Brian BanksPembroke$47K
- Anne-Margaret BotelhoMattapoisett$46K
- Sherrie UrenaWorcester$21K
- Irina DauphineeHanover$18K
- Schree PettigrewNew Bedford$18K
- Sherryl RosenLynn$16K
- Kevin NardoneWorcester$16K
- Edward TiminskiWorcester$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.